A Natural Androgen Receptor Antagonist Induces Cellular Senescence in Prostate Cancer Cells
Open Access
- 1 November 2014
- journal article
- research article
- Published by The Endocrine Society in Molecular Endocrinology
- Vol. 28 (11) , 1831-1840
Abstract
We have previously identified a natural occurring, androgen receptor-specific antagonist. Atraric acid (AA) inhibits the transactivation of the androgen receptor (AR) and androgen-mediated growth of AR-expressing human prostate cancer (PCa) cell lines. Here we show that AA treatment of living cells provokes molecular changes of AR signaling. In addition to a deceleration of nuclear translocation a block of the intramolecular amino/carboxy (N/C)-terminal interaction of the AR was observed. Furthermore, using high-resolution confocal fluorescence microscopy, a reduced speckle formation of the AR was observed in line with an increased intranuclear mobility of the receptor. This suggests decreased DNA binding of the AR, which is further indicated by an impaired chromatin recruitment of the AR to the prostate-specific antigen promoter and enhancer shown by chromatin immunoprecipitation experiments. Using inhibitors of the non-receptor tyrosine kinase Src or Akt, known interaction partners of AR, reduced the level of androgen-induced cellular senescence suggesting a partly non-genomic pathway to induce cellular senescence by AA. Using PP2 (4-Amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine) pyrimidine or Akt inhibitors, inhibitors of the nonreceptor tyrosine kinase Src or Akt, known interaction partners of AR, reduced the level of androgen-induced cellular senescence, suggesting a partly nongenomic pathway to induce cellular senescence by AA. Treatment of LNCaP cells with AA is associated with hypophosphorylation of the retinoblastoma tumor suppressor and an increase of p16 expression, whereas the p53-p21 signaling pathway seems not be affected by AA treatment. Analyzing human PCa tissue samples treated with AA ex vivo also indicates an induction of cellular senescence associated with an increase of p16 expression but not p21. Taken together, these data indicate that AA exhibits novel features to inhibit AR amino/carboxy-terminal interaction, the AR-mediated nuclear activities and growth of PCa cells.Keywords
This publication has 31 references indexed in Scilit:
- Androgen Deprivation-Induced Senescence Promotes Outgrowth of Androgen-Refractory Prostate Cancer CellsPLOS ONE, 2013
- A multi-parameter imaging assay identifies different stages of ligand-induced androgen receptor activationCytometry Part A, 2013
- Id1 Is Down-Regulated by Hepatocyte Growth Factor via ERK-Dependent and ERK-Independent Signaling Pathways, Leading to Increased Expression of p16INK4a in Hepatoma CellsMolecular Cancer Research, 2009
- Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate CancerScience, 2009
- AR Inhibitors Identified by High-Throughput Microscopy Detection of Conformational Change and Subcellular LocalizationACS Chemical Biology, 2009
- The natural compound atraric acid is an antagonist of the human androgen receptor inhibiting cellular invasiveness and prostate cancer cell growthJournal of Cellular and Molecular Medicine, 2008
- AR, the cell cycle, and prostate cancerNuclear Receptor Signaling, 2008
- Compartmentalization of androgen receptor protein–protein interactions in living cellsJournal of Cell Biology, 2007
- Antiandrogens prevent stable DNA-binding of the androgen receptorJournal of Cell Science, 2005
- Senescence in premalignant tumoursNature, 2005